A Practical Skills Course on New and Emerging Targets for Crohn’s Disease: Equipping NPs and PAs to Enhance Patient–Provider Therapeutic Connections to Optimize Outcomes

The goal of this continuing education activity is to enhance learners’ knowledge, competence, and performance in patient-centered care for CD using a treat-to-target approach, assessing and discussing bowel urgency, and advancing clinical and endoscopic outcomes for patients to improve quality of life.

• Apply expert consensus T2T guidance when evaluating treatment response and treatment advancement in patients with moderate-to-severe CD

• Leverage noninvasive imaging methods to assess mucosal and transmural inflammation in patients with CD

• Leverage expert guidance and evidence-based communication strategies that engage and empower patients to discuss the burden of CD—including bowel urgency—during patient visits 

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Primary Author

Emily Bennett has no relevant financial relationships to disclose.

Agelina E. Collins, MSN, ANP-BC: consultant/advisor/speaker: AbbVie, Janssen, Lilly, Takeda.

Bruce E. Sands, MD, MS: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Galapagos, Genentech, Gilead, GlaxoSmithKline, Janssen/Johnson & Johnson, Lilly, Merck, Pfizer, Takeda, Teva; individual publicly traded stock/stock options: Ventyx Biosciences.

Kimberly Orleck, PA-C: consultant/advisor/speaker: AbbVie, Ardelyx, Janssen, Pfizer, Salix, Takeda.